Epigenetic Biomarkers and Diagnostics

Edited by: José Luis García-Giménez (Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain; Medicine and Dentistry School; Biomedical Research Institute INCLIVA, University of Valencia, Spain). Academic Press, Boston, 2016, doi:10.1016/B978-0-12-801899-6.01001-9, Available online 8 December 2015

Chapter 3 - Epigenetic Mechanisms as Key Regulators in Disease: Clinical Implications, Abdelhalim Boukaba, Fabian Sanchis-Gomar and José Luis García-Giménez, doi:10.1016/B978-0-12-801899-6.00003-6
Alterations in the epigenetic machineries deregulate different epigenetic substrates, which in turn might be implemented as clinical epigenetic biomarkers for diagnosis, prognosis, and monitoring a wide variety of pathological conditions.

Chapter 20 – DNA Methylation in Neurodegenerative Diseases, Sahar Al-Mahdawi, Sara Anjomani Virmouni and Mark A. Pook, Pages doi:10.1016/B978-0-12-801899-6.00020-6.
This review focuses on our current understanding of the role of DNA methylation and its potential as a biomarker in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, fragile X-associated tremor/ataxia syndrome, Friedreich ataxia, and spinocerebellar ataxia type 7

Chapter 21 - The Histone Code and Disease: Posttranslational Modifications as Potential Prognostic Factors for Clinical Diagnosis, Nicolas G. Simonet, George Rasti and Alejandro Vaquero, 417-445, doi:10.1016/B978-0-12-801899-6.00021-8.
In this chapter, we summarize the current knowledge on the implications of histone PTMs in diverse human pathologies. We focus on the identified changes in histone modifications and associated enzymes in human diseases, as well as on their potential role in clinical diagnosis.





Epigenetic Biomarkers and Diagnostics
Chapter 3 - Epigenetic Mechanisms as Key Regulators in Disease: Clinical Implications
Chapter 20 – DNA Methylation in Neurodegenerative Diseases
Chapter 21 - The Histone Code and Disease: Posttranslational Modifications as Potential Prognostic Factors for Clinical Diagnosis